Naseem Amin, MD

Executive Chairman, London, UK

Naseem joined the Arix Board in December 2019 and was appointed as Executive Chairman in April 2020. He is currently Chief Executive Officer of GMP-Orphan and Non-Executive Director of Bellerophon Therapeutics (Nasdaq: BLPH). He is has broad life sciences experience in both the US and Europe, having held senior positions in major healthcare businesses in R&D, business development, marketing, and in venture capital. Naseem has been a Venture Partner at Advent Life Sciences, Chief Scientific Officer of Smith and Nephew plc and led Business Development at Biogen and at Genzyme Therapeutics, where for both of these companies, he initiated and executed a number of acquisitions and partnerships. Naseem started his career at Baxter Healthcare where he had executive roles in marketing, product development and clinical research. Naseem is a qualified medical doctor, from the University College Medical School, London, and holds an MBA from the Kellogg Graduate School of Management, Northwestern University.